According to this systematic review and meta-analysis, when SGLT-2 inhibitors are used as an add-on treatment for metformin, the decrease in HbA1c and fasting blood glucose in East Asian T2DM patients was significantly greater than in non-Asian patients compared with metformin monotherapy. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.